Vicente Valero, MD
To determine whether the addition of carboplatin to an adjuvant chemotherapy regimen of doxorubicin/cyclophosphamide followed by paclitaxel will improve the invasive disease-free survival (IDFS) compared to doxorubicin/cyclophosphamide followed by paclitaxel when administered to patients with operable node-positive or high-risk node-negative triple-negative breast cancer.
Patients with operable node-positive or high-risk node-negative triple-negative breast cancer who have undergone either a mastectomy or lumpectomy.
Pre-activation: June 11, 2015
Activation: June 26, 2015
Canada Activation: August 24, 2015
Protocol and Other Documents
Available via the National Cancer Institute (NCI) Cancer Trials Support Unit (CTSU) website
A slide set overview of this trial is available here.
Site Initiation Visit Video
To access the site initiation video click here (You will be prompted to enter your CTEP IAM credentials to access the materials.)